Mini Health Technology Assessment of Secukinumab and Ixekizumab

Abstract

Abstract: Objective：To provide an evidence-based basis for plaque psoriasis by multi-dimensional evaluation of Secukinumab and Ixekizumab.Methods：According to the drug evaluation and scoring system in the "Quick Guide for Drug Evaluation and Selection in Chinese Medical Institutions"， the health technology evaluation was carried out for Secukinumab and Ixekizumab.Results：The scores of Secukinumab and Ixekizumab were 76 and 79.5 respectively.Both had positive efficacy. However， there are differences in safety， economy and health insurance attributes.Conclusion：Mini HTA can comprehensively evaluate drugs from multiple dimensions， and provide a basis for rational selection of Secukinumab and Ixekizumab in clinical practice.

Key words: font-size:medium, ">Secukinumab； Ixekizumab； Mini HTA；Plaque psoriasis

CLC Number:

REN Cong-cong, JIA Guang-wei, ZHOU Jun-ning, XU Xiao-yan, LIU Yan-hong, WANG Hong-yan. Mini Health Technology Assessment of Secukinumab and Ixekizumab[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 173-177.

References

[1]Govender M， Mueller DB， Basu D. Purchasing of medical equipment in public hospitals： the mini-HTA tool[J]. South African medical journal， 2011， 101(11)： 807-808.
     [2]Kidholm K， Ehlers L， Korsbek L， et al. Assessment of the quality of mini-HTA[J]. International journal of technology assessment in health care， 2009， 25(1)： 42-48.
     [3]唐惠林，门鹏，翟所迪.药物快速卫生技术评估方法及应用[J]. 临床药物治疗杂志，2016，14(2)：1-4.
     [4]中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018完整版] (J]. 中华皮肤科杂志，2019，52(10)：667-710.
     [5]赵志刚，董占军，刘建平.中国医疗机构药品评价与遴选快速指南[J]. 医药导报，2020，39(11)：1457-1465.
     [6]中华医学会皮肤性病学分会，中国医师协会皮肤科医师分会，中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021] (J]. 中华皮肤科杂志，2021，54(12)：1033-1047.
     [7]中华医学会皮肤性病学分会，中国医师协会皮肤科医师分会，中国中西医结合学会皮肤性病专业委员会.中国银屑病生物治疗专家共识(2019] (J]. 中华皮肤科杂志，2019，52(12)：863-871.
     [8]《中国关节病型银屑病诊疗共识（2020）》编写委员会专家组.中国关节病型银屑病诊疗共识(2020] (J]. 中华皮肤科杂志，2020，53(8)：585-595.
     [9]中华医学会皮肤性病学分会银屑病学组，中华医学会皮肤性病学分会儿童学组. 中国儿童银屑病诊疗专家共识(2021] (J]. 中华皮肤科杂志，2021，54(7)：559-581
     [10]Sbidian E， Chaimani A， Garcia-Doval I， et al. Systemic pharmacological treatments for chronic plaque psoriasis： a network meta-analysis[J]. Cochrane Database Syst Rev， 2017， 12(12)：CD011535.
     [11]Mahil SK， Ezejimofor MC， Exton LS， et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis： an updated network meta-analysis[J]. Br J Dermatol， 2020， 183(4)：638-649.
     [12]Bilal J， Berlinberg A， Bhattacharjee S， et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab， secukinumab， ixekizumab， brodalumab， guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis[J]. J Dermatolog Treat， 2018， 29(6)：569-578.
     [13]Armstrong AW， Soliman AM， Betts KA，et al. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis： A Network Meta-analysis[J]. Dermatol Ther (Heidelb)， 2021， 11(3)：885-905.
     [14]Sbidian E， Chaimani A， Afach S， et al. Systemic pharmacological treatments for chronic plaque psoriasis： a network meta-analysis[J]. Cochrane Database Syst Rev， 2020，1(1)：CD011535.
     [15]Xu S， Gao X， Deng J， et al. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis： a multiple-treatments meta-analysis[J]. J Dtsch Dermatol Ges， 2021， 19(1)：47-56.
     [16]Sawyer LM， Malottki K， Sabry-Grant C， et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis： A systematic review and network meta-analysis of PASI response[J]. PLoS One， 2019， 14；14(8)：e0220868.
     [17]Jabbar-Lopez ZK， Yiu ZZN， Ward V， et al. Quantitative Evaluation of Biologic Therapy Options for Psoriasis： A Systematic Review and Network Meta-Analysis[J]. J Invest Dermatol， 2017， 137(8)：1646-1654.
     [18]Sbidian E， Chaimani A， Garcia-Doval I， et al. Systemic pharmacological treatments for chronic plaque psoriasis： a network meta-analysis[J]. Cochrane Database Syst Rev， 2021， 4(4)：CD011535.
     [19]He H， Wu W， Zhang Y， et al. Model-Based Meta-Analysis in Psoriasis： A Quantitative Comparison of Biologics and Small Targeted Molecules[J]. Front Pharmacol， 2021，12：586827.
     [20]de Carvalho AV， Duquia RP， Horta BL， et al. Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis： A Systematic Review and Meta-Analysis of Randomized Clinical Trials[J]. Drugs R D， 2017， 17(1)：29-51.
     [21]Cui L， Chen R， Subedi S， et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis： A systematic review and meta-analysis of randomized controlled trials[J]. Int Immunopharmacol， 2018， 62：46-58.
     [22]Loft ND， Vaengebjerg S， Halling AS， et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis： a systematic review and meta-analysis of phase III studies[J]. J Eur Acad Dermatol Venereol， 2020， 34(6)：1151-1160.
     [23]薛朝军，余克富，靳会欣，等.5种程序性细胞死亡蛋白1抑制剂的Mini卫生技术评估[J]. 中国医院药学杂志，2020，40(15)：1638-1642，1662.
     [24]邱博，王相冲，李从欣，等.医院卫生技术评估在口服保肝类药物遴选评价中的应用[J]. 医药导报，2021，40(10)：1443-1449.
     [25]付强强，嵇承栋，许畅，等.基于医疗机构需求的Mini-卫生技术评估[J]. 解放军医院管理杂志，2018，25(2)：131-134.